… This study showed the difference of pemetrexed efficacy by histologic type, and this result
supports the treatment-by-histology effect observed in the past pivotal phase III studies. Higher …

… to predict the lack of efficacy of cancer chemotherapy rather … shown no difference in
response rates between patients with … cantly lower in patients with pretreatment lymphocytopenia. …

… risk patients with metastatic renal cell carcinoma. The role of temsirolimus in pretreated patients
… However, these differences were not statistically significant which is most likely related to …

… safety for heavily pretreated patients with advanced and metastatic esophageal cancer
whose disease progressed after 2 or more lines of therapy (including 15 of 121 patients [12.4%] …

… patients with NSCLC and PS ≥2 [Citation18]. Thus, compared to the RCTs, our study included
more frail and heavily pretreated patients, … Nevertheless, the mOS of patients with PS ≥2 …

… in anthracycline and taxane resistant or pretreated patients with locally advanced or metastatic
… alone, although there was no difference in other efficacy outcomes. Both vinorelbine and …

… The primary efficacy endpoint for this study was the proportion of patients with a sustained
… This difference was significant in patients with a baseline HCV-RNA >800,000 IU/mL, but …

… Analysis of the baseline characteristics shows a population of pretreated patients with mCRC…
Treatment goals in this patient population may differ from those of patients receiving earlier …

… was no difference in the pretreatment antibody level between male and female patients (p =
… To reveal any relationship between pretreatment antibody levels and efficacy, it is necessary …

… Conversely, patients receiving monotherapy presented statistically significant difference
in OS according to the risk group, whereas this effect was not observed for those treated with …